Text or WhatsApp Richard at (808) 600-9260
Lion crestHealthcareInvestmentBanking.com

The Healthcare M&A Process, Step by Step

A healthcare sale runs through 11 stages, from readiness and data room to integration under the buyer. If the buyer is private equity, expect to sell as an add-on to an existing platform whose template fixes many of the terms. Healthcare adds two hard gates. Diligence on referral arrangements and billing is where deals get repriced. And regulatory notices, where they apply, set the earliest closing date.

Data as of November 20, 2026. Every figure below names its source, population and period, with full links under Sources. Figures marked "our arithmetic" are calculated from those sources, with assumptions stated. Worked examples marked "illustrative" use hypothetical figures.

The 11 Stages of a Healthcare Sale and the Gate at Each One

For the sequence as a flowchart, see the healthcare M&A timeline.

# Stage What happens Healthcare-specific gate Key document Who leads
1 Readiness and data room Financials cleaned up, contracts and compliance files organized Self-review of physician compensation, referral relationships and billing Data room index Owner, CFO, healthcare counsel
2 Advisor selection Seller interviews bankers or brokers, counsel and accountants Advisor's record in healthcare deals in your specialty Engagement letter Owner
3 Valuation Earnings normalized, payer mix and provider productivity tested Post-sale physician pay benchmarked, because it drives the add-back Valuation analysis Sell-side advisor, QoE accountant
4 Confidential marketing Teaser to screened buyers, NDA, then the CIM Limits on sharing patient data, staff confidentiality Teaser, NDA, confidential information memorandum (CIM) Sell-side advisor
5 IOIs and management meetings Buyers give non-binding value ranges and meet the physicians Buyer's plan for physician employment, rollover equity and MSO structure IOI Advisor and owner
6 LOI and exclusivity Price, structure, exclusivity and conditions agreed Exclusivity start date, outside date and regulatory extensions LOI Owner, advisor, counsel
7 Confirmatory diligence Financial, legal, operational and regulatory review Referral arrangements, ownership structure, billing and coding, licensure, payer contracts Diligence request list, QoE report Buyer and its advisors
8 Regulatory notices Federal premerger screen and state transaction notices Waiting periods and possible state review can set the earliest closing date Filings counsel identifies for the deal Counsel for both sides
9 Definitive agreement Purchase agreement and ancillary agreements negotiated Compliance representations, indemnity for pre-closing billing Purchase agreement, physician employment agreements Counsel
10 Closing Funds flow, consents, transfers Payer change-of-control consents, enrollment and licensure updates Closing checklist, funds flow memo Counsel, buyer, seller
11 Integration and transition Systems, staff and reporting combined, earnouts tracked Compliance program under the new owner Transition services agreement Buyer and seller physicians

What sets the pace in each phase

Phase Stages What controls the calendar What the seller can do about it
Preparation 1 to 3 How complete the data room and QoE are Finish both before marketing
Marketing 4 and 5 Number of qualified buyers and how fast they move A screened buyer list and one firm IOI deadline
Exclusivity to signing 6, 7 and 9 Diligence findings and how fast requests are answered A complete room, issues disclosed up front, a named owner for every request
Signing to closing 8 and 10 The longest regulatory clock, then payer consents Start filings as soon as the documents exist and send payer notices early
After closing 11 Earnout periods, escrow release dates, rollover exit Calendar every date and the data you are entitled to see

Three stages decide most outcomes.

Readiness. Owners skip it more often than any other stage, and it costs the least to get right. See preparing a healthcare company for sale and the sell-side readiness checklist.

The LOI. Once you sign, exclusivity bars talks with other buyers. The outside date has to cover every regulatory clock your deal triggers, plus an automatic extension if a regulator opens a review. If the outside date falls before the clocks run out, you renegotiate from a weaker position.

Diligence and notices together. File as soon as the required deal documents exist, while diligence is still running. Find out at the LOI stage which documents each filing needs, because a missing document delays the filing.

Who Buys Practices: 1,029 PE-Backed Healthcare Deals in 2025

The Private Equity Stakeholder Project's "Private Equity Healthcare Deals: 2025 in Review" tracked 1,029 PE-backed healthcare deals in calendar 2025, involving 420 platform companies and 708 investment firms. PESP built the count from PitchBook and LevinPro HC and says the final number is likely an underestimate. It counts PE-backed deals only, not sales to health systems, strategic operators or family offices investing without a PE fund.

Deal type, PE-backed healthcare, calendar 2025 (PESP) Deals Share of 1,029 (our arithmetic)
Add-on acquisitions 664 64.5%
Growth investments 214 20.8%
Leveraged buyouts (new platforms) 151 14.7%
Total 1,029 100%
Private equity healthcare deals in 2025, by deal type (deals)
Add-on acquisitions664Growth investments214Leveraged buyouts151

PESP counts 1,029 deals in total and says the count is likely an underestimate.

Chart data
Add-on acquisitions664
Growth investments214
Leveraged buyouts151

Source: Private Equity Stakeholder Project, PE healthcare deals 2025 in review

Practices and products are different markets

PESP's total mixes provider businesses with software and device businesses that are priced on different metrics. Split its five busiest subsectors before you read anything into the total.

Group, PE-backed deals, calendar 2025 (PESP) Subsectors Deals Share of 1,029 (our arithmetic)
Provider and practice businesses Dental care 149, outpatient care 148, behavioral health 56 353 34.3%
Product and software businesses Health IT 151, medtech 117 268 26.0%
All other subsectors Not broken out in this table 408 39.7%

The "all other" row is 1,029 minus the five named subsectors and assumes PESP assigns each deal to one subsector (our assumption). A practice owner should plan from the provider rows, not the headline total.

Provider subsector, PE-backed deals, calendar 2025 Deals What it means for a seller
Dental care (PESP) 149 PESP reports 95% were add-ons by PE-owned platforms, about 142 deals (our arithmetic: 95% of 149 is 141.6)
Outpatient care (Becker's ASC Review reporting PESP data) 148 119 were add-ons, 80.4% (our arithmetic). Top specialties by count: dermatology 24, eye care 22, oncology 9
Behavioral health (PESP) 56 Fewest deals of PESP's five busiest subsectors

Dermatology and eye care together made up 46 of the 148 outpatient deals in 2025, 31.1% (our arithmetic on the same PESP data).

The add-on share is the number to act on. Across all 1,029 PE-backed healthcare deals in 2025 it was 64.5%. In dental it was 95%, and in outpatient care 80.4%. A dental or dermatology owner selling to private equity will most likely sell to a platform that already has a compensation model, an MSO structure and an integration playbook. That template sets most of the terms. A seller large enough to be a platform can run a broader auction and has more say on rollover, governance and employment terms. Deal databases define deals differently, so treat PESP's totals as directional and its add-on shares as the planning signal.

Why buyers keep coming back to practices: the CMS National Health Expenditure fact sheet reports that physician and clinical services spending grew 8.1% to $1,109.7 billion in 2024, and CMS projects it will grow 5.5% a year on average from 2025 to 2034. Payer mix explains the diligence focus on billing. Medicare made up 21% of 2024 national health spending and private health insurance 31%, per the same fact sheet.

Decision table: platform or add-on

Your profile Likely buyer role What you can negotiate What the buyer's template usually fixes
Single site, one or two owner-physicians Add-on Price, earnout milestones, your employment term, transition length Compensation formula, MSO fee, systems, branding
Multi-site group with a management layer and room to grow by acquisition Platform Rollover size and rights, board seats, management equity, growth budget Sponsor's hold period and exit plan
Multi-site group in a specialty where the buyer already has a platform Add-on with bargaining power A higher price for scale, local leadership roles, physician equity pools Back-office integration
Healthtech or services business Platform or strategic Valuation basis (revenue or EBITDA), retention packages Product roadmap after closing

Hospital and health system deals: a separate market

Kaufman Hall tracks announced hospital and health system transactions, a different population from PESP's PE-backed deals. Do not add or compare the two sets of counts.

Period Months covered Announced hospital and health system transactions (Kaufman Hall data, via Becker's Hospital Review)
Q1 2026 3 22
Q2 2026 3 18
Q3 2026 3 16
2026 through September 30 9 56
Full year 2025 12 46

Read both lines of this table. The quarterly and full-year counts come from Becker's reporting of Kaufman Hall data. We could not check each figure against Kaufman Hall's own reports, so confirm them before relying on them. Nine months of 2026 already exceed all of 2025, which Becker's, citing Kaufman Hall, describes as the lowest annual count since tracking began in 2011. But the count fell every quarter of 2026, and Kaufman Hall's Q3 2026 press release (October 13, 2026) says the Q3 count of 16 matched Q3 2025. The year's gain came in the first half. The quarterly run rate is flat against last year.

Size, not volume, is the 2026 story. The same release reports $8.2 billion of transacted revenue in Q3 2026 and an average seller size approaching $586 million in annual revenue. It counted two mega mergers in Q3, the third straight quarter with mega mergers, and said 2026 could become a record year for deals in which the smaller party has more than $1 billion in annual revenue. Not-for-profits made most of the Q3 acquisitions, and divestitures made up nearly one-third of announced deals.

A practice owner should watch this when the buyer is a health system. The release puts hospital operating margin at 2.5% year to date including allocations, with nearly 43% of hospitals operating at a loss, both as of August 2026. Non-labor expenses rose 6% year to date per adjusted discharge against 2025, with supply expenses up 5% and drug expenses up 6%. Our read, not a finding in the release: a system buyer working under those margins has less room for generous compensation guarantees and capital commitments, so expect those terms to be tested hard.

The 10-Item Healthcare Data Room to Finish Before the CIM

Build the ten-item core below, then add one folder for the questions your profile raises. A roll-up needs integration results for each prior acquisition. A value-add story needs evidence for every claimed margin gain. A young business needs ramp data by provider and location. The healthcare data room checklist gives the full folder structure.

  1. A quality of earnings report from an accountant who knows healthcare reimbursement, with owner compensation normalized and each adjustment explained.
  2. Payer mix by payer and location, with collection rates and recoupment history.
  3. A provider roster with licenses, DEA registrations, board certifications, credentialing status and payer enrollment for each clinician.
  4. Every physician employment, independent contractor, medical director and partnership agreement, with compensation formulas written out.
  5. Every financial relationship with a person or entity that refers patients, including leases, loans and service agreements.
  6. Compliance program documents: policies, training logs, internal and external billing audits, self-disclosures and payer audits.
  7. Patient privacy policies, risk assessments and breach history.
  8. Real estate leases and related-party property, with assignment and change-of-control terms.
  9. Payer contracts, with change-of-control and anti-assignment clauses flagged.
  10. Corporate records showing who owns the clinical entity and, if there is one, the MSO.

Load the source records (claims data, EHR reports, signed contracts), not only the summaries. A buyer that can trace a summary to its source in minutes has less reason to widen diligence or ask for a larger escrow. Before management meetings, ask each bidder which folder its team will open first and make sure that folder is complete. A finished room before the LOI also defeats the delivery-triggered exclusivity term covered below.

Choosing an Advisor and How Buyers Build the Price

A sell-side advisor runs the process: the CIM, the buyer list, the IOIs and the LOI negotiation. Fees vary by firm and deal size. See how to choose a healthcare investment banker for how bankers and brokers are paid. Look up every firm and banker on your shortlist in FINRA BrokerCheck, a free record of registration and disclosure history.

Judge candidates by how much they ask before they pitch. Count their questions about your goals, partners, payer mix and post-sale plans before they show you a buyer list or a value. An advisor who quotes a multiple in the first meeting has not seen your quality of earnings or your payer contracts.

Questions for each advisor candidate:

Normalized EBITDA: where the price starts

Every bidder starts from trailing, realized earnings verified by a quality of earnings report. In healthcare the adjustment that matters most is owner-physician pay, because the normalized figure becomes the employment agreement the physician signs at closing.

Worked example (illustrative figures): normalizing a practice's EBITDA

Line Amount
Reported EBITDA $1,800,000
Add back: owner-physician pay above market ($900,000 paid minus $550,000 market replacement) +$350,000
Add back: one-time EHR migration cost +$120,000
Subtract: related-party rent $60,000 below market, reset to market at closing -$60,000
Adjusted EBITDA $2,210,000

The $350,000 add-back holds only if the physician signs for $550,000 after closing. At an illustrative 8x multiple (an assumption, not a market rate), adjusted EBITDA of $2,210,000 supports $17.68 million of enterprise value. If the physician negotiates $650,000 instead, the add-back falls to $250,000, adjusted EBITDA falls to $2,110,000, and enterprise value at 8x falls to $16.88 million. Each $100,000 of extra post-sale salary costs $800,000 of price at that multiple (our arithmetic). Decide which number you want before the LOI, not after.

Headline price versus cash at closing

The enterprise value in the LOI is not the cash you receive. Debt, rollover, escrow and deal costs come out first. In this example every percentage applies to equity value so the bases reconcile. LOIs define these bases differently, so ask each bidder which figure its rollover and escrow percentages apply to.

Worked example (illustrative figures), continuing from the $17.68 million enterprise value above

Line Basis (assumption) Amount
Enterprise value 8x adjusted EBITDA of $2.21M $17.680M
Less: practice debt repaid at closing Assumed -$1.200M
Equity value Enterprise value minus debt $16.480M
Less: rollover equity 20% of equity value -$3.296M
Cash consideration before holdbacks Equity value minus rollover $13.184M
Less: indemnity escrow 5% of equity value -$0.824M
Less: seller's deal costs (advisor, legal, QoE) Assumed flat figure, not a market rate -$0.500M
Cash to the seller at closing, before tax $11.860M

Our arithmetic. On these assumptions, cash at closing is about 67% of the headline enterprise value ($11.86M divided by $17.68M). The rollover and escrow are deferred value, not lost value, but neither is guaranteed. Escrow size turns on what diligence finds and on whether the buyer insures the representations, so the 5% here is a starting assumption. A working capital adjustment, not modeled, can move the figure in either direction. Ask every bidder to fill in this waterfall on its own terms before you compare LOIs.

Public market multiples: a ranking, not a price

Public market multiples show how investors rank healthcare business models. They are not a price for a private practice. Listed companies are larger and more liquid, and they do not depend on a single owner.

US public company EV/EBITDA, data as of January 2026 (Damodaran, NYU Stern) Firms in sample Multiple
Healthcare Information and Technology 115 21.27
Healthcare Products 204 19.78
Drugs (Pharmaceutical) 228 15.25
Healthcare Support Services 104 11.17
Hospitals/Healthcare Facilities 31 8.86
Total market excluding financials 4,822 16.95

In Damodaran's January 2026 data, Health IT trades at about 1.9 times the support services multiple (21.27 divided by 11.17) and about 2.4 times facilities (21.27 divided by 8.86), both our arithmetic. That gap is why a healthtech seller and a services seller should not borrow each other's comparables. Set your asking range with current healthcare valuation multiples and the QoE prep checklist.

Buyer type shapes terms as much as price

Buyer type What it typically wants What to watch
Private equity platform First acquisition in a specialty, with founders staying on Rollover equity terms and the sponsor's exit plan
Private equity add-on Smaller practice folded into an existing platform The platform's template sets compensation, MSO and integration terms
Health system Employs physicians directly Thin system margins put pressure on pay guarantees and capital commitments
Strategic operator Your geography or service line Overlap with its own sites can draw antitrust or state review
Family office Flexible hold period and structure Decision process varies widely. See our family office healthcare investing guide
Individual physician or small group A practice it can run itself If financed through the SBA 7(a) program, the program sets a loan limit that can change, so confirm the current rule with the lender. A larger price may need buyer equity, seller financing or another lender

IOIs, the LOI and When the Exclusivity Clock Starts

Outreach starts with an anonymous teaser. Interested buyers sign an NDA and receive the CIM, then submit IOIs: non-binding value ranges with a short note on structure. After management meetings, the seller picks one buyer and signs an LOI covering price, the split between cash and rollover, any earnout, exclusivity and the main closing conditions.

Read the exclusivity clause as closely as the price. A common buyer term starts exclusivity on delivery of the requested documents rather than at signing. That keeps the seller off the market longer than the stated period.

Worked example (illustrative dates). A seller signs an LOI on March 1, 2027 with 45 days of exclusivity that starts when the requested items are delivered. Delivery finishes March 31, so exclusivity runs to May 15, 2027. The seller is off the market for 75 days, not 45.

Negotiate both fixes. One is a complete data room before signing, so the clock starts at signing. The other is a fixed end date for exclusivity, with a short, defined extension only if the seller delivers late. Exclusivity and the regulatory outside date are separate clocks, and the LOI needs both. The LOI and term sheet red flags checklist covers the other terms to test.

Building the outside date

Input Who supplies it How it feeds the LOI
A. Date the filing documents will exist (signed LOI or draft agreement, depending on the filing) Counsel and advisor Start of every regulatory clock
B. Longest notice or waiting period your deal triggers Counsel A plus B is the earliest possible close
C. Time a regulator can add if it opens a review Counsel Automatic extension, not part of the base date
D. Time to collect payer consents and update enrollment Advisor and billing team Buffer added to the base date
Outside date Negotiated A plus B plus D, extending by C if a review opens

If a buyer refuses the automatic extension in row C, it is asking you to carry the regulatory risk. Price that in or walk.

Cash now versus rollover

The buyer's hold period drives the value of any rollover. Your second payday comes when the buyer resells. A short hold means either an earlier exit or pressure to grow fast before it.

Worked example (illustrative figures). Offer A is $20.0 million all cash. Offer B is $22.0 million with 30% rolled into the buyer's equity: $15.4 million in cash at closing and $6.6 million rolled. Both offers pay at least $15.4 million in cash, so that amount drops out of the comparison. The real choice is $4.6 million of extra cash today (Offer A) against a $6.6 million rolled stake paid at exit (Offer B).

Assumptions: 5-year hold, 8% annual return available on cash, pre-tax Offer A Offer B
Cash at closing $20.0M $15.4M
Extra $4.6M of cash, invested at 8% for 5 years $6.76M n/a
Rolled stake value at exit needed to break even n/a $6.76M
Rolled stake if its value grows 50% by exit n/a $9.90M (Offer B ahead by about $3.1M)
Rolled stake if its value falls 30% by exit n/a $4.62M (Offer B behind by about $2.1M)

Our arithmetic: $4.6 million times 1.08 to the fifth power is about $6.76 million. For Offer B to break even, the $6.6 million rolled stake has to be worth about $6.76 million at exit, a gain of about 2.4% in total over five years, not per year. The growth and loss rows are scenarios, not expected returns. None of the rows models taxes, fees, dilution or where the rolled stake sits in the capital structure, which are covered below.

Tax can widen Offer B's edge. The model is pre-tax. If the rollover can be structured to defer tax on the rolled portion until exit, Offer B may compare better after tax than this table shows. Offer A's extra $4.6 million may be taxed in the year of sale, while tax on the rolled $6.6 million may wait until exit.

The model leaves out four things that decide the real answer. Platform debt can wipe out a minority stake even when the business grows. Later funding rounds and management equity grants dilute your share. Fees and preferred terms can come ahead of common equity at exit. And the rolled stake cannot be sold until the buyer exits, which may come later than planned or not at all. Get the buyer's capital structure and the rollover's exact terms before you treat Offer B's headline as higher. Run your own offers through the rollover equity calculator.

Earnouts and escrows

Worked example (illustrative figures). A $3.0 million earnout pays in full if the practice reaches $2.5 million of EBITDA in year two and pays nothing below $2.2 million, with a straight line between. At $2.35 million of EBITDA the seller collects half, $1.5 million (our arithmetic: $0.15 million into a $0.3 million band). If the buyer moves your highest-margin service line to another platform site, year-two EBITDA can fall below the floor through no fault of yours. Write the accounting rules, the integration limits and your access to the data into the earnout terms.

An escrow holds back part of the price against indemnity claims. On an illustrative $20.0 million price, a 10% escrow held for 18 months keeps $2.0 million out of your hands until release. Push for a release schedule with partial payouts, a cap tied to specific risks found in diligence, and a short claims window.

Questions for every bidder before you sign an LOI:

Confirmatory Diligence: Referrals, Billing and Payer Contracts

Confirmatory diligence is where healthcare deals get repriced or die. Buyers look for liabilities that carry over to them, above all overpayments and referral arrangements they cannot defend. Our healthcare compliance due diligence guide covers the background.

Diligence area What buyers request Red flag buyers look for How findings hit the deal
Physician referral and compensation arrangements Every compensation formula, medical director agreement and lease with a referral source Pay formulas tied to ordered services, director fees with no time records, below-market leases to referral sources Refund exposure the buyer inherits, priced as special indemnities or escrow
Ownership structure Org chart for the clinical entity and any MSO, with management agreements An MSO fee with no support for how it was set, a physician owner with no real role Structure rebuilt before closing, which adds time
Billing and coding External claims sample, audit history High error rates, unusual modifier patterns Findings become escrow or indemnity amounts
Licensure and enrollment Roster with license, DEA and enrollment status Lapsed registrations, enrollment gaps Gaps interrupt billing after closing
Patient privacy and data security Risk assessments, policies, business associate agreements No recent risk assessment, unreported incidents Buyers price in remediation
Payer contracts Every contract with change-of-control terms flagged Contracts that terminate or require consent on a sale Cash flow drops during re-contracting, especially in an asset deal

Findings usually turn into price adjustments, special indemnities or escrows rather than a walk-away. A seller who runs the same review before marketing can disclose issues and price them on its own terms. An issue the buyer finds during exclusivity gets priced on the buyer's terms. See healthcare deal structures for how escrows, indemnities, rollover and earnouts work, and the buyer due diligence checklist for the request list to expect.

Diligence runs both ways. Ask each bidder for its written diligence request list before you sign. If a bidder has none, press for shorter exclusivity or a firm deadline for requests. If you are rolling equity, you are investing in the buyer. Send your own questionnaire on its debt, compliance history, hold period and exits, and search SEC EDGAR for notices showing whether the platform or its parent has raised private capital. Our guide to reverse due diligence on healthcare buyers has the full question set.

How Regulatory Review Sets the Closing Date

Two layers of review can apply to a practice sale: federal premerger notice and state healthcare transaction notice laws. State laws vary widely and can reach deals far smaller than any federal filing. The business consequences are the same wherever they apply:

Seller's pre-LOI checklist for the regulatory calendar

Gather these facts before the LOI so the regulatory screen runs in one pass and the outside date rests on real inputs, not guesses.

Item to prepare Effect on the calendar Who owns it
List of every state where you and the buyer operate clinical sites, by location Each state in the footprint is a possible notice and a possible new critical date Owner and buyer, collected by advisor
The buyer's existing practices in your specialty and local markets Overlap is what draws a closer look, whether or not a filing applies Advisor, confirmed by buyer
Revenue and asset figures for the practice and any related entities, from the QoE The screen runs on measured figures, not the headline price CFO and QoE accountant
A target signing date and the draft documents each filing will need Filings may not be able to start until the documents exist (row A of the outside date table) Counsel and advisor
Payer contracts ranked by revenue, with consent and notice terms flagged Sets the order of payer outreach and the buffer in row D Billing team
A written split of filing costs and the cost of delay Avoids reopening price if a review runs long Negotiated in the LOI
A staff and patient communications plan in case a notice becomes public Some filings are visible, and news can reach staff before you do Owner and advisor

Using the dates already on this page: a seller who signs on March 1, 2027 with a complete room and these seven items in hand can start any filing that the signed LOI supports right away instead of weeks into exclusivity. Some filings may need a signed definitive agreement or other documents first, so confirm with counsel which documents each filing requires. If physician pay, referral sources or an MSO are part of the deal, settle them before the LOI as well. Our management services organizations guide covers the structure.

High-risk area: Antitrust and state deal review

Antitrust review and state health care transaction review are areas where the rules are strict, change often and depend on your state, your deal structure and your facts, so this page explains how they can affect timing and structure and leaves current thresholds and filing rules to your counsel. Engage a healthcare attorney (and a securities attorney if you are rolling equity into the buyer) and bring these questions.

Questions to ask your attorney

1. Could this deal trigger a federal premerger notice, and which figures would be measured to decide?

  • Why ask: The size tests may not be measured on the headline price, and the answer shapes the earliest closing date and the outside date in the LOI.
  • What can go wrong: If a filing surfaces after you sign, the closing can slip past the outside date and you may end up renegotiating during exclusivity.

2. Which states in our combined footprint may call for notice or review of this transaction, and at what point in the deal could each filing be due?

  • Why ask: State rules differ, can reach small practice deals and can set a later critical date than any federal process.
  • What can go wrong: A state filing found late can push back the closing, add cost or make the deal public before staff and patients have heard from you.
  • How states have handled it: Some states, including California, now require advance notice of certain health care transactions (HCAI). These rules and their start dates keep changing, so confirm the current requirements with your attorney.

3. Could the buyer's private equity backing, its MSO structure or a sale-leaseback of our real estate bring this deal into a state review it might otherwise avoid?

  • Why ask: Some states now look past the clinical entity to the investors, management companies and property arrangements around it.
  • What can go wrong: A structure chosen for tax or financing reasons may widen the review and lengthen the calendar.
  • How states have handled it: Some states, including Massachusetts, have widened their review to reach deals involving equity investors, sale-leasebacks and management services organizations (Massachusetts Legislature). Ask your attorney whether any such review applies to your deal.

4. Does the buyer's existing ownership of practices in our specialty and market create antitrust risk, even if no filing applies?

  • Why ask: For an add-on sale, the overlap between your practice and the platform's other sites is what can draw a regulator's attention.
  • What can go wrong: A challenge can delay or unwind a deal, and it may affect the value of any rollover equity or earnout tied to the platform.
  • Example: In 2023 federal antitrust regulators sued an anesthesiology platform and its private equity backer over a roll-up of Texas practices, and the companies disputed the claims (Reuters). Ask your attorney how cases like this may bear on your deal and any rolled equity.

5. How should the LOI allocate regulatory risk, including the outside date, an automatic extension, who pays filing costs and what happens if a regulator opens a review?

  • Why ask: These terms are easiest to win before exclusivity starts, and they decide who carries the cost of delay.
  • What can go wrong: Without an extension or a clear cost split, a long review can give the buyer room to walk away or reopen the price.

6. What can we share with the buyer, and when, about payer rates, physician pay and patient volumes before closing?

  • Why ask: Diligence and integration planning call for sensitive data, and the buyer may run practices that compete with yours.
  • What can go wrong: Sharing competitively sensitive information too early, or acting as one business before closing, can create its own regulatory problems.

7. If I roll equity into the platform, how could a regulatory challenge to the buyer's other acquisitions affect my stake?

  • Why ask: A rolled stake is an investment in the whole platform, including deals you had no part in.
  • What can go wrong: A review or challenge elsewhere in the platform may slow growth, delay the exit or reduce what your stake is worth.

Other topics to raise with your attorney

  • Physician compensation and every financial arrangement with a referral source
  • Rules on lay ownership of clinical practices in your states and how the MSO structure is set up
  • Medicare and commercial payer enrollment changes when ownership changes
  • Tax treatment of the deal structure, the purchase price allocation and any rolled equity
  • Securities questions on rollover equity and how your sell-side advisor is registered and paid

Closing Day and the First Year Under the Buyer

At closing, the funds flow runs, third-party consents come in and payer enrollment and licensure updates are filed. Physicians sign employment agreements with the buyer or its affiliated clinical entity, and most sellers work through a transition period. Rollover equity ties part of your value to the buyer's next exit and cannot be sold before then in most deals. An earnout pays only if the contract's milestones are met on the contract's measurement terms.

Decide your post-sale role before you sign the LOI, because it changes which terms are worth accepting.

Your plan after closing Terms worth accepting Terms to resist
Leave within a year More cash at closing, short transition, small or no earnout Long employment term, large rollover, multi-year earnout
Stay three to five years Meaningful rollover, earnout tied to metrics you control, leadership role Earnout tied to platform-wide results, weak information rights
Stay and lead a platform Board seat, management equity, growth budget Sponsor control over add-on choices without your input

Post-closing checklist for the seller:

Healthcare M&A Process FAQs: Timing, Add-Ons, Federal Notice and LOI Prep

How long does the healthcare M&A process take?

Three things set the length. Before the LOI, it depends on how ready the seller is. A finished data room and a quality of earnings report remove weeks of back-and-forth. After the LOI, the longest regulatory notice or review the deal triggers sets the earliest closing date. The regulator controls that clock, and faster diligence does not move it. The last stretch is payer consents and enrollment updates, which have to be finished before claims pay under the new owner. Build the LOI's outside date from those three inputs, with an automatic extension if a regulator opens a review.

Will my practice sell as a platform or an add-on?

If the buyer is private equity, the data points to an add-on. The Private Equity Stakeholder Project (PESP) tracked 1,029 PE-backed healthcare deals in calendar 2025, across all subsectors including health IT and medtech. Of those, 664 were add-ons (64.5%, our arithmetic) and 151 were leveraged buyouts that created new platforms. The add-on share is higher in the practice subsectors. PESP reports that 95% of its 149 dental deals in 2025 were add-ons by PE-owned platforms. Becker's ASC Review, reporting PESP data, counts 119 add-ons among 148 outpatient care deals in 2025 (80.4%, our arithmetic). These counts cover PE-backed deals only, not sales to health systems or other strategic buyers. An add-on buyer prices and structures the deal against its platform's existing model. A platform sale gives the seller more say on rollover, governance and employment terms.

Does selling my practice require a federal premerger filing?

Ask your attorney whether your deal may trigger a federal premerger notice. The size tests can change from year to year and are measured under their own rules, so the headline price may not be the figure that counts. The FTC publishes general information on its program. Run the screen before you sign the LOI, because a filing can add a waiting period that may set the earliest closing date. A deal below the federal line may still trigger a state healthcare transaction notice and can still draw antitrust review.

Is healthcare M&A activity increasing in 2026?

For hospitals and health systems, the 2026 count already beats 2025, but the quarterly pace is falling. Kaufman Hall counted 56 announced hospital and health system transactions from January through September 2026, against 46 in all of 2025, its lowest annual count since tracking began in 2011 (Becker's Hospital Review, reporting Kaufman Hall data). Quarterly counts fell from 22 to 18 to 16, and the Q3 count matched Q3 2025, so most of the gain came in the first half. For practices, PE activity is the closer gauge. PESP counted 1,029 PE-backed healthcare deals in calendar 2025, across all subsectors including health IT and medtech, and says that count is likely an underestimate.

What should I prepare before signing an LOI?

Build the data room first: a quality of earnings report, payer mix by payer, provider contracts and credentialing files, compliance and audit history, leases, payer contracts with change-of-control clauses flagged, and every financial relationship with a referral source. With a complete room, exclusivity can start at signing instead of when you finish delivering documents. Then decide your post-sale role, test every offer's cash at closing against its headline price, and set exclusivity and the outside date to fit the regulatory notices your deal triggers.

Sources